BrainParrot

Cheaper Cancer Medicines: What the New Margin Cap Means for Patients

GS2Full notePublished: · Updated:

Source: PIB (Press Information Bureau) · Read the original ↗

Summary

  • On 17 Oct 2026 the National Pharmaceutical Pricing Authority (NPPA) capped the trade margin at 30% of MRP on 137 non-scheduled anti-cancer medicines, patented ones included.
  • Revised prices take effect on 9 Nov 2026.
  • By 4 Nov 2026, 70 companies had reported revised MRPs for 120 drugs.
  • The highest cut so far is 96.45%, with estimated savings of Rs 3,357.49 crore.

UPSC relevance: GS2 – Social Justice/Health (drug pricing, affordable healthcare); GS3 – Economy (price regulation)

Key facts for Prelims

  • NPPA acted under Paragraph 19 of the DPCO, 2013, on 17 Oct 2026 (Order S.O. 5690(E), Ministry of Chemicals and Fertilizers). It covers 137 non-scheduled anti-cancer drugs, including patented ones.
  • The cap is 30% of MRP, excluding GST. GST is added on top.
  • The base is the average distributor price of March 2026.
  • Revised prices are effective from 9 Nov 2026.
  • Trade margin is the gap between the stockist/distributor price and the MRP, excluding GST.
  • NLEM: first created in 1996, revised in 2003, 2011, 2015 and 2022. NLEM 2022 was released on 13 Sept 2022 by Dr Mansukh Mandaviya. It was prepared by the Standing National Committee on Medicines (SNCM), with WHO standards checked. Vision: "Sabko Dawai, Sasti Dawai".
  • Cancer-care support ecosystem named in the article:
  • screening at Ayushman Arogya Mandirs
  • free HPV vaccination for girls
  • cashless hospital treatment under AB-PMJAY
  • lower-cost medicines at Jan Aushadhi Kendras
  • AMRIT pharmacies (Affordable Medicines and Reliable Implants for Treatment)
  • eSanjeevani teleconsultation, including oncology care
  • DPCO 2013 sits under the Essential Commodities Act, 1955. NPPA works under the Department of Pharmaceuticals (Ministry of Chemicals and Fertilizers).

Data and details

  • By 4 Nov 2026, 70 companies had reported revised MRPs for 120 of the 137 drugs.
  • The highest single MRP reduction is 96.45%. Average reductions run from 20% to 70%.
  • Estimated savings: Rs 3,357.49 crore.
  • The article says the Order sets a formula for the maximum retail price. The formula itself is not reproduced in the text.
  • The release does not give the savings period or a per-patient saving. The Rs 3,357.49 crore figure should be cited as an "estimate".

Static–dynamic linkage

  • Drug prices in India are regulated through the Drugs (Prices Control) Order (DPCO), 2013, an order under the Essential Commodities Act, 1955.
  • Only "scheduled" formulations, i.e. essential medicines on the NLEM, have a government-fixed ceiling price. The 137 drugs here are non-scheduled, so there was no ceiling price on them.
  • The state therefore did not fix the manufacturer's price. It capped the markup between the distributor price and the MRP, using its extraordinary power under Paragraph 19.
  • This is a form of regulation aimed at the supply chain rather than the product price. It targets out-of-pocket expenditure, a major cause of impoverishment from illness.

Syllabus mapping: GS2 – Social Justice: health, human-resource issues; GS2 – Governance: regulatory bodies; GS3 – Economy: price regulation and inclusive growth

Background primer

National Pharmaceutical Pricing Authority (NPPA)

What it is:
the body that implements the DPCO and monitors prices of scheduled and non-scheduled formulations.
Founded:
constituted through a Government of India Resolution dated 29 Aug 1997 as an independent regulator for drug pricing; it is an attached office of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
Members:
not confirmed from a trusted source in this search.
Mandate:
implements the DPCO and monitors prices of scheduled and non-scheduled formulations.
Why it matters:
to keep essential medicines affordable and to prevent arbitrary or excessive pricing.

Drugs (Prices Control) Order (DPCO), 2013

What it is:
an order issued under the Essential Commodities Act, 1955.
Founded:
it replaced DPCO 1995 and shifted drug pricing from a cost-based to a market-based methodology.
Mandate:
ceiling prices for scheduled formulations. For NLEM drugs, the medicines are in the First Schedule of the DPCO and NPPA fixes their ceiling prices.

Trade Margin Rationalisation (TMR)

What it is:
limits the profit margin distributors and retailers can add to a drug's price.
Why it matters:
very high margins add profit along the chain and inflate what the patient pays well above the manufacturer's selling price.

Additional context

  • The 2026 order builds on NPPA's 2019 pilot TMR, which capped trade margins on 42 anti-cancer drugs at 30%. That pilot cut MRPs by up to 90% for 526 brands.
  • An Expert Committee under the Directorate General of Health Services recommended the 137 drugs.
  • Pembrolizumab, Durvalumab and Osimertinib are among the covered drugs. Others are immunotherapies for 20+ cancer types, denosumab, pegfilgrastim and bevacizumab.
  • Manufacturers must inform NPPA of revised prices within seven days of the notification.
  • Para 19 has earlier been used for select non-scheduled anti-cancer drugs, six COVID-essential medical devices and knee implants.
  • A Parliamentary Standing Committee on Chemicals and Fertilizers report (6 Aug 2026) reviewed NPPA's role.
    • It noted there is no set timeframe for building a permanent TMR framework into the DPCO.
    • It also noted that 82% of market share is non-scheduled formulations.
    • Several hospitals and retailers offer 20–60% discounts on MRP.
  • NPPA found average markups of about 170% on non-scheduled cancer drugs, with some up to 700%.

Mains dimensions

  • Why intervene: non-scheduled drugs have no ceiling price. Cancer drugs are costly, and a high trade margin inflates the patient's price far above the manufacturer's selling price.
  • Regulatory design: TMR is a lighter-touch tool than price fixing. It does not touch the manufacturer's base price or the launch price, so very high launch prices stay unaddressed.
  • Coverage of patented drugs: the cap expressly includes patented drugs, so widely used medicines such as Pembrolizumab, Durvalumab and Osimertinib fall within it. This extends the trade-margin relief to newer immunotherapies and targeted therapies.
  • Implementation:
  • The cap depends on companies reporting revised MRPs (120 of 137 drugs reported by 4 Nov).
  • Retail and hospital pharmacy compliance must be monitored.
  • Supply continuity matters, since margins shrink for stockists and retailers.
  • Continuum of care: the release places the cap alongside screening, HPV vaccination, AB-PMJAY cashless treatment, Jan Aushadhi and AMRIT pharmacies, and eSanjeevani. The link to Universal Health Coverage and lower out-of-pocket spending is the Mains angle.
  • Way forward:
  • A permanent TMR framework within the DPCO (flagged by the Standing Committee).
  • Transparent trade-price disclosure.
  • Stronger generic and biosimilar competition.
  • Wider data coverage for monitoring.

Possible Mains question

**GS2, 15 marks:** "Trade-margin rationalisation of anti-cancer drugs is a shift from ceiling pricing to supply-chain regulation. Examine its rationale and limitations in making cancer care affordable in India."

Related topics

  • Essential Commodities Act, 1955 and National Pharmaceutical Pricing Policy
  • NLEM and Jan Aushadhi / PMBJP
  • AB PM-JAY and out-of-pocket expenditure
  • Pricing of medical devices (stents, knee implants) under the DPCO
  • National Programme for Prevention and Control of Non-Communicable Diseases (NP-NCD)

Topics: GS2

How we write and check these notes →

All current affairs of 6 November 2026 → · UPSC Current Affairs